In a nutshell:
The report provides interim guidance to health-care providers based on the reported results of the trial, which indicated that tenofovir disoproxil fumarate (TDF) plus emtricitabine (FTC) taken orally once a day as preexposure prophylaxis (PrEP) is safe and partially effective in reducing HIV acquisition among MSM when provided with regular monitoring of HIV status and ongoing risk-reduction and PrEP medication adherence counseling.You might also be interested in:
The CDC on Pre-Exposure Prophylaxis (PrEP)
Return Home: http://drughealth.blogspot.com/
GMP Posters
The Health, Drug, Prescription, and GMP Supersite Gift Store
Return to Mobile Home: http://drughealth.prohost.mobi/




0 comments:
Post a Comment